Cu(II)ATSM ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	4
6	Parkinson disease	1

2. Amyotrophic lateral sclerosis

---

Clinical trials : 645 /  Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04313166 (ClinicalTrials.gov)	March 19, 2020	15/3/2020	Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001	A Treatment Continuation Study for Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Who Have Successfully Complete Study CMD-2019-001	Amyotrophic Lateral Sclerosis	Drug: Cu(II)ATSM	Collaborative Medicinal Development Pty Limited	NULL	Completed	18 Years	75 Years	All	55	Phase 2	Australia
2	NCT04082832 (ClinicalTrials.gov)	September 30, 2019	2/9/2019	CuATSM Compared With Placebo for Treatment of ALS/MND	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Cu(II)ATSM in Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease	Amyotrophic Lateral Sclerosis	Drug: Cu(II)ATSM;Drug: Placebos	Collaborative Medicinal Development Pty Limited	NULL	Recruiting	18 Years	75 Years	All	80	Phase 2/Phase 3	Australia
3	NCT03136809 (ClinicalTrials.gov)	January 18, 2018	28/4/2017	ALS Treatment Extension Study	A Treatment Continuation Study for Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Who Have Successfully Completed Study CMD-2016-001	Amyotrophic Lateral Sclerosis	Drug: Cu(II)ATSM	Collaborative Medicinal Development Pty Limited	NULL	Active, not recruiting	18 Years	75 Years	All	28	Phase 1/Phase 2	Australia
4	NCT02870634 (ClinicalTrials.gov)	November 16, 2016	10/8/2016	Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND	A Phase 1 Single and Multiple Dose Escalation and Pharmacokinetic Study of Cu(II)ATSM Administered Orally to Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease	Amyotrophic Lateral Sclerosis;Motor Neuron Disease	Drug: Cu(II)ATSM	Collaborative Medicinal Development Pty Limited	NULL	Completed	18 Years	75 Years	All	50	Phase 1	Australia

6. Parkinson disease

---

Clinical trials : 2,307 /  Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03204929 (ClinicalTrials.gov)	August 14, 2017	28/6/2017	Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease	A Phase 1 Dose Escalation Study of Cu(II)ATSM Administered Orally to Patients With Early Idiopathic Parkinson's Disease	Parkinson Disease	Drug: Cu(II)ATSM	Collaborative Medicinal Development Pty Limited	NULL	Completed	30 Years	N/A	All	31	Phase 1	Australia

Back to top